Business
RenovoRx and Imugene Announce Collaboration to Deliver Oncolytic Virus Therapy Using Proprietary Trans-Arterial Micro-Perfusion (TAMP™) Platform
Collaboration will explore trans-arterial delivery of Imugene’s CF33 oncolytic virus utilizing RenovoRx’s TAMP therapy platform. TAMP is expected to enable
About this update from Renovorx, Inc.
[{"type":"text","content":"\n\nCollaboration will explore trans-arterial delivery of Imugene’s CF33 oncolytic virus utilizing RenovoRx’s TAMP therapy platform.\n\n\n\nTAMP is expected to enable localized, targeted delivery of CF33 to difficult-to-access tumors, such as pancreatic and liver tumors\n\n\n\n LOS ALTOS, Calif. & SYDNEY--(BUSINESS WIRE)--\nRenovoRx, Inc. (“RenovoRx”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing targeted combination therapies, and Imugene Ltd (“Imugene”) (ASX: IMU), a clinical-stage immuno-oncology company, today announced a strategic research collaboration to optimize the delivery of Imugene’s oncolytic virus therapy with RenovoRx’s TAMP (Trans-Arterial Micro-Perfusion) therapy platform for the treatment of difficult-to-access tumors.\n\n\n“We believe the synergy between RenovoRx’s trans-arterial drug delivery system and our CF33 oncolytic virus platform has the potential to facilitate treatment of difficult-to-access cancers and help patients,” said Leslie Chong, Managing Director & Chief Executive Officer of Imugene.\n\n\n“Our collaboration with Imugene is an important milestone for RenovoRx as we expand our pipeline from exclusively treating locally advanced disease to treating metastatic disease with immunotherapy,” said Shaun Bagai, Chief Executive Officer, RenovoRx. “We look forward to combining our proprietary TAMP platform with Imugene’s CF33 oncolytic virus with the goal of optimizing clinical benefits for patients.”\n\n\nAs part of the collaboration, Imugene and RenovoRx will investigate the ability to administer Imugene’s CF33 oncolytic virus technology with RenovoRx’s TAMP therapy platform. The ability to treat difficult-to-access tumours, such as pancreatic and liver cancers, by delivering CF33 trans-arterially may be valuable to cancer patients compared to traditional administration methods where dense fibrous tissue and lack of blood vessels supplying the tumours have been shown to limit therapy uptake.\n\n\nThe TAMP platform is designed to ensure precise therapeutic delivery to a target tissue. In a study presented at the Society of Interventional Radiology 2019 Annual Meeting, the proprietary platform demonstrated a 100-fold (two orders of magnitude) increase in local tissue concentration with TAMP compared to conventional IV delivery as well as advantages compared to off-the-shelf intr...